Design Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $588 | $0 |
Gross Profit | -152 | -159 | 294 | -153 |
EBITDA | -21,569 | -20,259 | -16,545 | -16,093 |
EBIT | -21,721 | -20,418 | -16,694 | -16,246 |
Net Income | -19,083 | -17,715 | -13,651 | -13,039 |
Net Change In Cash | 0 | 0 | 588 | 0 |
Free Cash Flow | -14,528 | -16,861 | -9,860 | -9,530 |
Cash | 19,703 | 13,667 | 22,563 | 30,328 |
Basic Shares | 56,859 | 56,757 | 56,681 | 56,620 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -596 | -537 | -466 | -129 |
EBITDA | -48,992 | -66,325 | -67,187 | -35,702 |
EBIT | -49,588 | -66,862 | -67,593 | -35,831 |
Net Income | -49,588 | -66,862 | -58,617 | -35,533 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -272,069 | 296,190 | ||
Free Cash Flow | -43,445 | -58,816 | -52,235 | -30,915 |
Cash | 22,563 | 21,200 | 26,500 | 298,569 |
Basic Shares | 56,587 | 55,984 | 55,707 | 45,940 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.34 |
2025-03-31 | -$0.31 |
2024-12-31 | -$0.24 |
